{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"20"}],"title":"No"},{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}],"title":"Yes"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"description":"Number of participants with chronic GVHD graded by the method of Przepiorka et al, which evaluates skin, joints, oral, ocular, hepatic, esophagus, GI, respiratory, platelet, and musculoskeletal involvement, in stages from 0 to 3.","groups":[{"description":"Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the CLINIMACS Device\n\nAra-C: day-8 through day-5\n\n3 g/m2 q 12 hours\n\nCyclophosphamide: day-7 and day-6\n\n45 mg/kg\n\nCampath-1H: day-3 through day-1\n\nDosing for children:\n\n5 - 15kg : 3mg IV in 30ml NS\n\n15.1 - 30kg : 5mg IV in 50ml NS\n\n\\>30 kg : 10mg IV in 100ml NS\n\nAdults will receive 10mg IV in 100ml NS\n\nTotal Body Irradiation: day-4 through day-1\n\n175 cGy x 2 at 24 cGy/min\n\nStem Cell Infusion: Stem cells are infused on day 0","id":"OG000","title":"CLINIMACS Device"},{"description":"Subjects will receive transplant conditioning with Ara-C, Cyclophosphamide, Campath-1H, Total Body Irradiation and will then receive T cell depleted stem cell infusion processed by the ISOLEX Device\n\nAra-C: day-8 through day-5\n\n3 g/m2 q 12 hours\n\nCyclophosphamide: day-7 and day-6\n\n45 mg/kg\n\nCampath-1H: day-3 through day-1\n\nDosing for children:\n\n5 - 15kg : 3mg IV in 30ml NS\n\n15.1 - 30kg : 5mg IV in 50ml NS\n\n\\>30 kg : 10mg IV in 100ml NS\n\nAdults will receive 10mg IV in 100ml NS\n\nTotal Body Irradiation: day-4 through day-1\n\n175 cGy x 2 at 24 cGy/min\n\nStem Cell Infusion: Stem cells are infused on day 0","id":"OG001","title":"ISOLEX Device"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Patients surviving more than 100 days were evaluable for chronic GvHD. Of the 46 participants at baseline, eight participants in CLINIMACS and six in ISOLEX were not evaluable for chronic GVHD and were not included in this analysis.","reportingStatus":"POSTED","timeFrame":"Up to 1 Year","title":"Patients With Chronic GVHD","type":"SECONDARY","unitOfMeasure":"Participants"}